J&J says AI cut drug candidate timelines in half and sped up filings fast

The company claims AI slashed a key step in drug discovery

Johnson & Johnson says it’s using artificial intelligence to accelerate multiple stages of drug development. The firm reports that AI has halved the time to identify promising new drug candidates. It also says AI is streamlining manufacturing and significantly reducing the time required to prepare regulatory documentation, potentially shortening the path from concept to approval.